Six-month Electrical Performance of the First Dual-Chamber Leadless Pacemaker.

Aveir DR Leadless pacemaker chronic pacing dual-chamber helix-fixation pacing capture threshold sensed amplitude

Journal

Heart rhythm
ISSN: 1556-3871
Titre abrégé: Heart Rhythm
Pays: United States
ID NLM: 101200317

Informations de publication

Date de publication:
30 Apr 2024
Historique:
received: 05 04 2024
revised: 23 04 2024
accepted: 26 04 2024
medline: 3 5 2024
pubmed: 3 5 2024
entrez: 2 5 2024
Statut: aheadofprint

Résumé

The first dual-chamber leadless pacemaker (DC-LP) system consists of two separate atrial and ventricular devices that communicate to maintain synchronous atrioventricular pacing and sensing. The initial safety and efficacy were previously reported. Evaluate the chronic electrical performance of the DC-LP system. Patients meeting standard dual-chamber pacing indications were enrolled and implanted with the DC-LP system (Aveir DR, Abbott), including right atrial and ventricular helix-fixation LPs (ALP, VLP). Pacing capture threshold, sensed amplitude, and pacing impedance were collected using the device programmer at prespecified time points from 0-6 months post-implant. De novo devices were successfully implanted in 381 patients with complete 6M data (62% male; age 69±14 years; weight 82±20 kg; 65% sinus node dysfunction, 30% AV block). ALPs were implanted predominantly in the right atrial appendage anterior base; VLPs primarily at the mid-to-apical right ventricular septum. From implant to 1 month, pacing capture thresholds (0.4 ms pulse width) improved in both ALPs (2.4±1.5 to 0.8±0.8 V, P<0.001) and VLPs (0.8±0.6 to 0.6±0.4 V, P<0.001). Sensed amplitudes improved in both ALPs (1.8±1.3 to 3.4±1.9 mV, P<0.001) and VLPs (8.8±4.0 to 11.7±4.2 mV, P<0.001). Impedances were stable in ALPs (334±68 to 329±52 Ω, P=0.17) and reduced in VLPs (789±351 to 646±190 Ω, P<0.001). Electrical measurements remained relatively stable from 1-6 months post-implant. No differences in electrical metrics were observed among ALP or VLP implant locations. This first in-human evaluation of the new dual-chamber leadless pacemaker system demonstrated reliable electrical performance throughout the initial 6-month evaluation period.

Sections du résumé

BACKGROUND BACKGROUND
The first dual-chamber leadless pacemaker (DC-LP) system consists of two separate atrial and ventricular devices that communicate to maintain synchronous atrioventricular pacing and sensing. The initial safety and efficacy were previously reported.
OBJECTIVE OBJECTIVE
Evaluate the chronic electrical performance of the DC-LP system.
METHODS METHODS
Patients meeting standard dual-chamber pacing indications were enrolled and implanted with the DC-LP system (Aveir DR, Abbott), including right atrial and ventricular helix-fixation LPs (ALP, VLP). Pacing capture threshold, sensed amplitude, and pacing impedance were collected using the device programmer at prespecified time points from 0-6 months post-implant.
RESULTS RESULTS
De novo devices were successfully implanted in 381 patients with complete 6M data (62% male; age 69±14 years; weight 82±20 kg; 65% sinus node dysfunction, 30% AV block). ALPs were implanted predominantly in the right atrial appendage anterior base; VLPs primarily at the mid-to-apical right ventricular septum. From implant to 1 month, pacing capture thresholds (0.4 ms pulse width) improved in both ALPs (2.4±1.5 to 0.8±0.8 V, P<0.001) and VLPs (0.8±0.6 to 0.6±0.4 V, P<0.001). Sensed amplitudes improved in both ALPs (1.8±1.3 to 3.4±1.9 mV, P<0.001) and VLPs (8.8±4.0 to 11.7±4.2 mV, P<0.001). Impedances were stable in ALPs (334±68 to 329±52 Ω, P=0.17) and reduced in VLPs (789±351 to 646±190 Ω, P<0.001). Electrical measurements remained relatively stable from 1-6 months post-implant. No differences in electrical metrics were observed among ALP or VLP implant locations.
CONCLUSION CONCLUSIONS
This first in-human evaluation of the new dual-chamber leadless pacemaker system demonstrated reliable electrical performance throughout the initial 6-month evaluation period.

Identifiants

pubmed: 38697271
pii: S1547-5271(24)02525-6
doi: 10.1016/j.hrthm.2024.04.091
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Gerhard Hindricks (G)

Deutsches Herzzentrum der Charite, Berlin, Germany.

Rahul Doshi (R)

HonorHealth Cardiac Arrhythmia Group, Scottsdale, Arizona, USA.

Pascal Defaye (P)

Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.

Derek V Exner (DV)

Foothills Medical Centre, Calgary, Canada.

Vivek Y Reddy (VY)

Mount Sinai Fuster Heart Hospital, New York, NY, USA.

Reinoud E Knops (RE)

Amsterdam UMC, Amsterdam, The Netherlands.

Robert Canby (R)

Texas Cardiac Arrhythmia Institute, Austin, Texas, USA.

Morio Shoda (M)

Tokyo Women's Medical University, Tokyo, Japan.

Maria Grazia Bongiorni (MG)

San Rossore Private Hospital and Medical Center, Pisa, Italy.

Petr Neužil (P)

Na Homolce Hospital, Prague, Czech Republic.

Thomas Callahan (T)

Cleveland Clinic Foundation, Cleveland, Ohio, USA.

Sri Sundaram (S)

South Denver Cardiology, Littleton, CO, USA.

Nima Badie (N)

Abbott, Sylmar, California, USA.

James E Ip (JE)

Weill Cornell Medicine/ New York Presbyterian Hospital, New York, NY, USA. Electronic address: jei9008@med.cornell.edu.

Classifications MeSH